Michael D B Swedberg

发表

The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats.

A. Fink-Jensen, P. Suzdak, Michael D B Swedberg, 1992, European journal of pharmacology.

1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists.

L Jeppesen, J S Ward, F. Bymaster, 1998, Journal of medicinal chemistry.

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse.

Michael D B Swedberg, 2016, Journal of pharmacological and toxicological methods.

A proactive nonclinical drug abuse and dependence liability assessment strategy: a sponsor perspective

Michael D B Swedberg, 2013, Behavioural pharmacology.

AZD9272 and AZD2066: Selective and Highly Central Nervous System Penetrant mGluR5 Antagonists Characterized by Their Discriminative Effects

Michael D B Swedberg, P. Raboisson, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 2000, Schizophrenia Research.

NNC 19-1228 and NNC 22-0031, novel neuroleptics with a “mesolimbic-selective” behavioral profile

Michael D B Swedberg, M. Scheideler, J. Hansen, 1997, Psychopharmacology.

Prediction and Modeling of Effects on the QTc Interval for Clinical Safety Margin Assessment, Based on Single-Ascending-Dose Study Data with AZD3839

Michael D B Swedberg, C. Pollard, M. Bridgland-Taylor, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans.

G. Badger, W. Bickel, Michael D B Swedberg, 2001, The Journal of pharmacology and experimental therapeutics.

Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease

F. Bymaster, L. Farde, P. Suzdak, 1997 .

Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 2000, Schizophrenia research.

Muscarinic agonists as analgesics. Antinociceptive activity versus M1 activity: SAR of alkylthio-TZTP's and related 1,2,5-thiadiazole analogs.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1995, Life sciences.

Xanomeline: An Efficacious and Specific M1 Receptor Agonist — Preclinical Update

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1994 .

Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndrome.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1997, Journal of medicinal chemistry.

Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX).

Michael D B Swedberg, T. Honoré, P. Jacobsen, 1995, The Journal of pharmacology and experimental therapeutics.

Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.

D. Wong, F. Bymaster, P. Suzdak, 1994, The Journal of pharmacology and experimental therapeutics.

Synthesis of novel GABA uptake inhibitors. Part 6: preparation and evaluation of N-Omega asymmetrically substituted nipecotic acid derivatives.

P. Suzdak, Michael D B Swedberg, J. Lau, 2001, Bioorganic & medicinal chemistry.

The mouse grid-shock analgesia test: pharmacological characterization of latency to vocalization threshold as an index of antinociception.

Michael D B Swedberg, 1994, The Journal of pharmacology and experimental therapeutics.

3-(5-Alkylamino-4-isoxazolyl)-1,2,5,6-tetrahydropyridines: a novel class of central nicotinic receptor ligands.

Michael D B Swedberg, K. Rimvall, P. Olesen, 1998, Bioorganic & medicinal chemistry.

Anticonvulsant profile of the imidazoquinazolines NNC 14-0185 and NNC 14-0189 in rats and mice.

P. Suzdak, Michael D B Swedberg, M. Judge, 1996, European journal of pharmacology.

Butylthio[2.2.2] (NNC 11-1053/LY297802): an orally active muscarinic agonist analgesic.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1997, The Journal of pharmacology and experimental therapeutics.

M1 receptor agonist activity is not a requirement for muscarinic antinociception.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1997, The Journal of pharmacology and experimental therapeutics.

A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions.

Michael D B Swedberg, M. Skinner, J. Valentin, 2013, Journal of pharmacological and toxicological methods.

Role of central noradrenaline neurons in the contextual control of latent inhibition in taste aversion learning

Michael D B Swedberg, T. Archer, A. Mohammed, 1986, Behavioural Brain Research.

Discriminative stimulus functions of CNS sedative drugs assessed by drug versus drug discrimination procedures in gerbils

Michael D B Swedberg, T. Järbe, 1998, Psychopharmacology.

Discriminative stimulus properties of drugs: a brief history and a selective review.

Michael D B Swedberg, T. Järbe, 1982, Scandinavian journal of psychology.

Evidence supporting lack of discriminative stimulus properties of a combination of naltrexone and morphine

Michael D B Swedberg, T. Järbe, P. Loman, 1979, Pharmacology Biochemistry and Behavior.

Approaches for Early Identification of Abuse Potential Liability

Michael D B Swedberg, 2019, Advanced Issue Resolution in Safety Pharmacology.

Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1999, The Journal of pharmacology and experimental therapeutics.

Potential role of muscarinic receptors in schizophrenia.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1999, Life sciences.

Inverse isostere strategies in the development of cholinergic agonists with multiple therapeutic potentials

F. Bymaster, Michael D B Swedberg, C. Mitch, 1997 .

Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity.

D. Wong, F. Bymaster, P. Suzdak, 1997, The Journal of pharmacology and experimental therapeutics.

3-(3-Alkylthio- 1,2,5-thiadiazol-4-yl)- 1 -azabicycles. Structure-activity relationships for antinociception mediated by central muscarinic receptors

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1996 .

Analgesic Effects of Vedaclidine, a Mixed Agonist ‚Äì Antagonist at Muscarinic Receptor Subtypes

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 2003 .

In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1997, Life sciences.

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane .

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1998, European journal of pharmacology.

Discriminative stimulus effects of intravenous l-nicotine and nicotine analogs or metabolites in squirrel monkeys

Michael D B Swedberg, S. Goldberg, J. Katz, 2004, Psychopharmacology.

Effects of chlormethiazole (Heminevrin®) on drug discrimination and open-field behavior in gerbils

Michael D B Swedberg, T. Järbe, P. Loman, 1978, Psychopharmacology.

Drug discrimination procedures: Differential characteristics of the drug A vs drug B and the drug A vs drug B vs no drug cases

Michael D B Swedberg, T. Järbe, 2004, Psychopharmacology.

Synthesis of novel GABA uptake inhibitors. 3. Diaryloxime and diarylvinyl ether derivatives of nipecotic acid and guvacine as anticonvulsant agents.

P. Suzdak, Michael D B Swedberg, R. Henry, 1999, Journal of medicinal chemistry.

Reinforcing Effects of Nicotinic Compounds Intravenous Self-administration in Drug-Naive Mice

Michael D B Swedberg, T. Rasmussen, 1998, Pharmacology Biochemistry and Behavior.

Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).

D. Wong, F. Bymaster, P. Suzdak, 1994, The Journal of pharmacology and experimental therapeutics.

Compound drug discrimination learning

Michael D B Swedberg, A. Hiltunen, T. Järbe, 1989 .

Preclinical Pharmacology of AZD2327: A Highly Selective Agonist of the δ-Opioid Receptor

T J Hudzik, Michael D B Swedberg, K. Bui, 2011, Journal of Pharmacology and Experimental Therapeutics.

A repeated test procedure to assess onset and duration of the cue properties of (-) delta 9-THC, (-) delta 8-THC-DMH and (+) delta 8-THC.

Michael D B Swedberg, R. Mechoulam, T. Järbe, 1981, Psychopharmacology.

Pharmacological mechanisms of action of flupirtine: a novel, centrally acting, nonopioid analgesic evaluated by its discriminative effects in the rat.

Michael D B Swedberg, S. Goldberg, H. Shannon, 1988, The Journal of pharmacology and experimental therapeutics.

Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive mice.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 2000, European journal of pharmacology.

Ethanol as a discriminative stimulus: effects of cyanamide, acetaldehyde and chlormethiazole.

Michael D B Swedberg, A. Hiltunen, T. Järbe, 1982, Medical biology.

Establishment of auditory discrimination and detection of tinnitus induced by salicylic acid and intense tone exposure in the rat

Michael D B Swedberg, F. Sederholm, 2013, Brain Research.

Drug discrimination procedures: Roles of relative stimulus control in two-drug cases

Michael D B Swedberg, T. Järbe, 1985, Psychopharmacology.

Synthesis of novel GABA uptake inhibitors. 4. Bioisosteric transformation and successive optimization of known GABA uptake inhibitors leading to a series of potent anticonvulsant drug candidates.

P. Suzdak, Michael D B Swedberg, J. Sorensen, 1999, Journal of medicinal chemistry.

Synthesis of Novel γ-Aminobutyric Acid (GABA) Uptake Inhibitors. Part 5. Preparation and Structure—Activity Studies of Tricyclic Analogues of Known GABA Uptake Inhibitors.

P. Suzdak, Michael D B Swedberg, J. Lau, 2001 .

Synthesis of novel gamma-aminobutyric acid (GABA) uptake inhibitors. 5.(1) Preparation and structure-activity studies of tricyclic analogues of known GABA uptake inhibitors.

P. Suzdak, Michael D B Swedberg, J. Sorensen, 2001, Journal of medicinal chemistry.

In vivo labeling of the central GABA uptake carrier with 3H-Tiagabine.

P. Suzdak, Michael D B Swedberg, C. Braestrup, 1992, Life Science.

Tolerance to the cognitive impairing effects but not the anticonvulsant effects of NO-328, a selective GABA uptake inhibitor

P. Suzdak, Michael D B Swedberg, M. Judge, 1990 .

mGluR5 Antagonist-Induced Psychoactive Properties: MTEP Drug Discrimination, a Pharmacologically Selective Non–NMDA Effect with Apparent Lack of Reinforcing Properties

Michael D B Swedberg, P. Raboisson, M. Ellgren, 2014, The Journal of Pharmacology and Experimental Therapeutics.

A behavioural operant discrimination model for assessment and pharmacological manipulation of visual function in rats

Michael D B Swedberg, M. Carlsson, Mikael A. Carlsson, 2010, Brain Research.

A repeated tests procedure to assess onset and duration of the cue properties of (−)Δ9-THC, (−)Δ8-THC-DMH and (+)Δ8-THC

Michael D B Swedberg, R. Mechoulam, T. Järbe, 1981, Psychopharmacology.

Drug Discrimination: Use in Preclinical Assessment of Abuse Liability

Michael D B Swedberg, A. Giarola, 2015 .

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse.

Michael D B Swedberg, 2016, Journal of pharmacological and toxicological methods.

Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.

J S Ward, F. Bymaster, Michael D B Swedberg, 1995, Journal of medicinal chemistry.

mGluR5 Antagonist-Induced Psychoactive Properties: MTEP Drug Discrimination, a Pharmacologically Selective Non–NMDA Effect with Apparent Lack of Reinforcing Properties

Michael D B Swedberg, P. Raboisson, M. Ellgren, 2014, The Journal of Pharmacology and Experimental Therapeutics.